Oxford BioMedica Plc advanced its lead vaccine and gene therapies in the clinic in 2010 while raising £20 million in new capital in January to support ongoing development activities. The company had a net loss in 2010 of £10.3 million. ---Subscribe to MedNous to access this article--- Company News
